First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.

ABNCoV2 - University of Copenhagen, Leiden University Medical Center, Bavarian Nordic, AdaptVac, ExpreS2ion, University of Tuebingen

http://www.ncbi.nlm.nih.gov/pubmed/36681093

Jan 22, 2023